Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 55Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pancreatic Neoplasms 6Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 3Biliary Tract Neoplasms 3Neoplasms 2Stomach Neoplasms 1Pancreatic Cancer Resectable 1Neoplastic Cells, Circulating 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Locally Advanced Pancreatic Adenocarcinoma 1Liver Neoplasms 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Breast Cancer Organoids 1Brain Neoplasms 1

Interventions

atezolizumab 5avelumab 4erdafitinib 1enfortumab vedotin 1darolutamide 1Therapeutics 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Radiotherapy 1Patient Reported Outcome Measures 1Nivolumab 1Mitomycin 1Magnetic Resonance Spectroscopy 1Laparoscopy 1Immunotherapy 1Histocompatibility Testing 1High-Throughput Nucleotide Sequencing 1Hematologic Tests 1Gemcitabine 1Focus Groups 1Educational Status 1Drug Therapy 1Defecation 1Cytological Techniques 1Cystoscopy 1Cisplatin 1Carboxylesterase 1Blood Cell Count 1Biomarkers 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Carcinoma, Transitional Cell × Gemcitabine × Clear all
NCT06120374 2025-12-30

Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC

Peking University First Hospital

Recruiting
178 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡